Antiviral resin composition, masterbatch for synthetic resin molding, and viral infection–inhibiting molded body

Abstract

The present invention provides an antiviral resin composition that makes it possible to maintain excellent viral infection inhibition effects even after wiping with water. This antiviral resin composition includes magnesium oxide, an auxiliary agent, and a synthetic resin. The auxiliary agent includes a nonionic surfactant or polyoxyalkylene glycol and therefore has excellent water resistance. A synthetic resin molded body that includes this antiviral resin composition maintains excellent viral infection inhibition effects even after contact with water caused by cleaning by wiping with water or the like or contact with a human hand or the like.

Description

Antiviral resin composition, synthetic resin molding masterbatch, and virus infection-preventing molded article

[0001] The present invention relates to an antiviral resin composition, a masterbatch for synthetic resin molding, and a virus infection-preventing molded article.

[0002] In recent years, in addition to the seasonal influenza virus epidemic, the novel coronavirus (COVID-19) has become a global pandemic.

[0003] Furthermore, highly pathogenic avian influenza viruses have mutated and been confirmed to infect humans, and there are also concerns about the SARS virus, which has an extremely high mortality rate, so anxiety about viruses is only increasing.

[0004] To address these problems, Patent Document 1 discloses an antiviral material comprising a metal oxide powder and a hydroxide, which enables the generation of hydroxyl radicals that inactivate viruses.

[0005] Patent Document 2 discloses an antiviral agent containing oxide and / or hydroxide powder.

[0006] Furthermore, synthetic resin molded articles are now used in a variety of applications, and as a countermeasure against viruses, antiviral properties are imparted to the synthetic resin molded articles by incorporating antiviral agents into the synthetic resin molded articles.

[0007] WO2009 / 098786 WO2005 / 013695

[0008] However, when a synthetic resin molded article is produced by incorporating the antiviral agents described in Patent Documents 1 and 2 into a synthetic resin, there is a problem in that when the surface of the synthetic resin molded article is brought into contact with water, for example by wiping with water, the antiviral properties (viral infection prevention effect) of the synthetic resin molded article are reduced due to its low water resistance.

[0009] The present invention provides an antiviral resin composition that can maintain an excellent viral infection-blocking effect even after wiping with water, as well as a synthetic resin molding masterbatch and a viral infection-blocking molded article that use the antiviral resin composition.

[0010] The antiviral resin composition of the present invention is characterized by comprising magnesium oxide, an auxiliary agent, and a synthetic resin, wherein the auxiliary agent comprises a nonionic surfactant or polyoxyalkylene glycol.

[0011] The synthetic resin molding masterbatch of the present invention is characterized by containing the above-mentioned antiviral resin composition.

[0012] The virus infection-blocking molded article of the present invention is characterized by containing the above-mentioned antiviral resin composition.

[0013] The antiviral resin composition of the present invention contains magnesium oxide, the above-described auxiliary agent, and a synthetic resin, and the antiviral resin composition has excellent water resistance. Therefore, a synthetic resin molded article containing the antiviral resin composition of the present invention maintains an excellent virus infection-blocking effect (hereinafter referred to as "water-resistant virus infection-blocking effect") even after contact with water due to cleaning such as wiping with water or contact with human hands.

[0014] The antiviral resin composition of the present invention contains magnesium oxide, an auxiliary agent, and a synthetic resin, and the auxiliary agent contains a nonionic surfactant or a polyoxyalkylene glycol.

[0015] In the antiviral resin composition, the total content of magnesium oxide, the auxiliary agent, and the synthetic resin is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, and more preferably 99% by mass or more.

[0016] [Magnesium oxide] The antiviral resin composition contains magnesium oxide. The magnesium oxide may be used alone or in combination of two or more kinds.

[0017] Magnesium oxide improves the water-resistant viral infection prevention effect of the antiviral resin composition, and therefore the antiviral resin composition preferably contains at least one magnesium oxide selected from the group consisting of light-burned magnesium oxide, burned magnesium oxide, and electro-fused magnesium oxide, more preferably light-burned magnesium oxide or electro-fused magnesium oxide, and more preferably light-burned magnesium oxide.

[0018] The content of light-burned magnesium oxide in magnesium oxide is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0019] The content of electrofused magnesium oxide in magnesium oxide is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0020] The content of dead-burned magnesium oxide in magnesium oxide is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0021] Light-burned magnesium oxide is magnesium oxide obtained by burning a mineral containing at least one of magnesium carbonate and magnesium hydroxide as a main component at 600 to 1000°C.

[0022] The MgO content in the light-burned magnesium oxide is preferably 80% by mass or more, more preferably 85% by mass or more, and even more preferably 90% by mass or more. The MgO content in the light-burned magnesium oxide is preferably 99.9% by mass or less. When the MgO content in the light-burned magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the antiviral resin composition is improved.

[0023] The CaO content in the light-burned magnesium oxide is preferably 0 to 3 mass%, more preferably 0 to 2.5 mass%, more preferably 0 to 2 mass%, more preferably 0.01 to 2 mass%, and even more preferably 0.01 to 1 mass%. When the CaO content in the light-burned magnesium oxide is within the above range, the water-resistant viral infection prevention effect of the antiviral resin composition is improved. In the present invention, a content of Compound A of 0 mass% means that Compound A is not contained.

[0024] The SiO content in the light-burned magnesium oxide is preferably 0 to 5 mass%, more preferably 0 to 3 mass%, and even more preferably 0 to 2 mass%. When the SiO content in the light-burned magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the antiviral resin composition is improved.

[0025] The content of Fe2O3 in the light-burned magnesium oxide is preferably 0 to 1 mass%, more preferably 0 to 0.5 mass%, more preferably 0 to 0.4 mass%, more preferably 0.0001 to 0.1 mass%, and more preferably 0.0005 to 0.05 mass%. When the content of Fe2O3 in the light-burned magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the antiviral resin composition is improved.

[0026] The contents of MgO, CaO, SiO, and FeO in magnesium oxide can be measured by the Fundamental Parameter (FP) method using an energy dispersive X-ray fluorescence analyzer, such as the one commercially available from PHILIPS under the trade name "PW1404."

[0027] Dead burned magnesium oxide is magnesium oxide obtained by burning a mineral containing at least one of magnesium carbonate and magnesium hydroxide as a main component at 1500°C or higher.

[0028] Electrofused magnesium oxide refers to a material produced by electro-melting magnesium oxide or a magnesium compound such as magnesium hydroxide or magnesium carbonate, and then pulverizing the resulting molten magnesium oxide, if necessary.

[0029] The content of MgO in the electro-fused magnesium oxide is preferably 85% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, and still more preferably 96% by mass or more. The content of MgO in the electro-fused magnesium oxide is preferably 99.9% by mass or less, and more preferably 99.0% by mass or less. When the content of MgO in the electro-fused magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the anti-viral resin composition is improved.

[0030] The content of CaO in the electro-fused magnesium oxide is preferably 0 to 3 mass%, more preferably 0.001 to 2.5 mass%, more preferably 0.002 to 2 mass%, more preferably 0.005 to 1.5 mass%, more preferably 0.01 to 1 mass%, and more preferably 0.05 to 0.8 mass%. When the CaO content in the electro-fused magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the anti-viral resin composition is improved.

[0031] The SiO content in the electro-fused magnesium oxide is preferably 0 to 5 mass%, more preferably 0.02 to 2 mass%, more preferably 0.03 to 1 mass%, and even more preferably 0.04 to 0.5 mass%. When the SiO content in the electro-fused magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the anti-viral resin composition is improved.

[0032] The content of Fe2O3 in the electro-fused magnesium oxide is preferably 0 to 1 mass%, more preferably 0.01 to 0.5 mass%, more preferably 0.02 to 0.4 mass%, more preferably 0.025 to 0.3 mass%, and still more preferably 0.03 to 0.1 mass%. When the content of Fe2O3 in the electro-fused magnesium oxide is within the above range, the water-resistant viral infection-preventing effect of the anti-viral resin composition is improved.

[0033] The specific surface area of ​​magnesium oxide is 20 m 2 / g or more is preferable, and 22m 2 / g or more is more preferable, 2 / g or more is more preferable, and 25m 2 / g or more is more preferable, and 27m 2 The specific surface area of ​​magnesium oxide is preferably 100 m / g or more. 2 / g or less is preferable, and 95m 2 / g or less is more preferable, 2 / g or less is more preferable, and 85m 2 When the specific surface area of ​​magnesium oxide is within the above range, the magnesium oxide and the auxiliary agent described below interact appropriately, improving the water-resistant viral infection-preventing effect of the antiviral resin composition.

[0034] The specific surface area of ​​magnesium oxide refers to a value measured by the BET method in accordance with ASTM D3037-93.

[0035] The D50 particle size of the magnesium oxide is preferably 0.1 μm or more, more preferably 0.2 μm or more, more preferably 0.3 μm or more, and more preferably 0.4 μm or more. The D50 particle size of the magnesium oxide is preferably 10 μm or less, more preferably 9 μm or less, more preferably 8 μm or less, more preferably 7 μm or less, preferably 6 μm or less, and more preferably 5 μm or less. When the D50 particle size of the magnesium oxide is 0.1 μm or more, aggregation of the antiviral resin composition is reduced and the antiviral resin composition can be uniformly incorporated into the substrate, thereby improving the water-resistant virus infection-blocking effect of the virus infection-blocking molded article. When the D50 particle size of the magnesium oxide is 50 μm or less, the surface area of ​​the antiviral resin composition increases, which tends to improve the water-resistant virus infection-blocking effect of the antiviral resin composition.

[0036] The D50 particle size of magnesium oxide refers to the particle size (50% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in the volume-based particle size distribution determined by laser scattering method is 50%.

[0037] The content of magnesium oxide in the antiviral resin composition is preferably 1 part by mass or more, more preferably 2 parts by mass or more, and more preferably 3 parts by mass or more, per 100 parts by mass of the total of magnesium oxide, auxiliary agent, and synthetic resin described below. The content of magnesium oxide in the antiviral resin composition is preferably 10 parts by mass or less, more preferably 9 parts by mass or less, more preferably 8 parts by mass or less, and more preferably 7 parts by mass or less, per 100 parts by mass of the total of magnesium oxide, auxiliary agent, and synthetic resin described below. When the content of magnesium oxide is 1 part by mass or more, the water-resistant viral infection prevention effect of the antiviral resin composition is improved. When the content of magnesium oxide is 10 parts by mass or less, the strength of the antiviral resin composition is easily maintained, which is preferable.

[0038] [Auxiliary Agent] The antiviral resin composition contains a nonionic surfactant or polyoxyalkylene glycol as an auxiliary agent. Although it has not been clearly elucidated, it is presumed that the antiviral resin composition contains the auxiliary agent, which reduces the removal of magnesium oxide by moisture or the reaction of magnesium oxide with moisture to form magnesium hydroxide, thereby imparting an excellent water-resistant viral infection prevention effect to the antiviral resin composition. The auxiliary agent may contain only one of a nonionic surfactant or a polyoxyalkylene glycol, or may contain both.

[0039] Furthermore, the nonionic surfactant and polyoxyalkylene glycol used as auxiliary agents do not have functional groups that become anionic or cationic when dissolved in water. The nonionic surfactant and polyoxyalkylene glycol moderately adsorb moisture without inhibiting the mechanism by which magnesium oxide denatures viral proteins, and therefore it is presumed that the antiviral resin composition exhibits excellent water-resistant viral infection prevention effects.

[0040] Thus, the antiviral resin composition exhibits an excellent water-resistant viral infection-preventing effect due to the synergistic effect of the combination of magnesium oxide and the above-mentioned auxiliary agent.

[0041] Examples of polyoxyalkylene glycols include polyethylene glycol, polypropylene glycol, polybutylene glycol, polyoxyethylene polyoxypropylene glycol, etc., and polyethylene glycol is preferred because it provides an excellent water-resistant viral infection prevention effect for the antiviral resin composition. The polyoxyalkylene glycols may be used alone or in combination of two or more.

[0042] The nonionic surfactant is not particularly limited, and examples thereof include polyoxyalkylene alkyl ethers, polyoxyethylene alkylphenyl ethers, fatty acid esters, polyoxyethylene distyrenated phenyl ethers, polyoxyethylene alkylamines, polyoxyethylene fatty acid amides, fatty acid alkanolamides, aliphatic alcohols, fatty acid alkylolamides, alkylalkanolamides, acetylene glycol, oxyethylene adducts of acetylene glycol, polyethylene glycol polypropylene glycol block copolymers, etc. The nonionic surfactants may be used alone or in combination of two or more.

[0043] The fatty acid ester is not particularly limited, and examples thereof include polyalkylene glycol fatty acid esters (e.g., polyalkylene glycol mono-fatty acid esters such as polyethylene glycol monostearate and polypropylene glycol monostearate, and polyalkylene glycol di-fatty acid esters such as polyethylene glycol distearate and polypropylene glycol distearate), sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, glycol fatty acid esters (e.g., ethylene glycol fatty acid esters and propylene glycol fatty acid esters), glycerin fatty acid esters (e.g., monoglycerides of saturated fatty acids, diglycerides of saturated fatty acids, monoglycerides of unsaturated fatty acids, diglycerides of unsaturated fatty acids), polyoxyethylene glycerin fatty acid esters, polyglycerin fatty acid esters, and sucrose fatty acid esters.

[0044] Fatty acid esters are excellent in imparting a water-resistant viral infection-preventing effect to the antiviral resin composition, and therefore preferred are sorbitan fatty acid esters (sorbitan saturated fatty acid esters are more preferred, and sorbitan monosaturated fatty acid esters are more preferred), glycerin fatty acid esters (fatty acid monoglycerides are preferred, and saturated fatty acid monoglycerides are more preferred), polyalkylene glycol fatty acid esters (polyalkylene glycol saturated fatty acid esters are more preferred, and polyalkylene glycol disaturated fatty acid esters are more preferred), and glycol fatty acid esters (alkylene glycol saturated fatty acid esters are more preferred, and alkylene glycol monosaturated fatty acid esters are more preferred), with polyalkylene glycol fatty acid esters being more preferred.

[0045] In the fatty acid ester, the total number of carbon atoms of the fatty acid used as the raw material is preferably 14 to 20, more preferably 15 to 19, and still more preferably 16 to 18, since this provides an excellent water-resistant viral infection inhibiting effect for the antiviral resin composition.

[0046] In the case of fatty acid esters, saturated fatty acids are preferred as the fatty acids used as raw materials, since they have an excellent water-resistant viral infection inhibiting effect on the antiviral resin composition.

[0047] The aliphatic alcohol is not particularly limited, and examples thereof include capryl alcohol (1-octanol), pelargonic alcohol (1-nonanol), capric alcohol (1-decanol), lauryl alcohol (1-dodecanol), myristyl alcohol (1-tetradecanol), cetyl alcohol (1-hexadecanol), palmitoleic alcohol (cis-9-hexadecan-1-ol), stearyl alcohol (1-octadecanol), isostearyl alcohol (16-methylheptadecan-1-ol), elaidyl alcohol (9E-octadecen-1-ol), cetostearyl alcohol (a mixture of cetearyl alcohol, cetyl alcohol, and stearyl alcohol), oleyl alcohol (cis-9-octadecen-1-ol), and linoleyl alcohol (9Z,12Z-octadecadien-1-ol).

[0048] The aliphatic alcohol is R 1 It is preferable that the compound has a structure represented by —OH. 1 is a monovalent aliphatic hydrocarbon group. 1 The hydrogen atoms in may be substituted with other substituents. Aliphatic hydrocarbons refer to hydrocarbons that belong to compounds (aliphatic compounds) other than aromatic compounds that have aromaticity. Aliphatic hydrocarbons are a concept that includes chain aliphatic hydrocarbons in which carbon atoms are bonded in a row, branched chain aliphatic hydrocarbons with a branched structure, and alicyclic hydrocarbons in which carbon atoms are bonded in a ring. A monovalent aliphatic hydrocarbon group refers to a monovalent substituent resulting from abstracting one hydrogen atom from an aliphatic hydrocarbon.

[0049] In the case of an aliphatic alcohol, the number of carbon atoms in the aliphatic alcohol is preferably 14 to 20, more preferably 15 to 19, and even more preferably 16 to 18, since this provides an excellent water-resistant viral infection inhibiting effect for the antiviral resin composition.

[0050] The polyoxyalkylene alkyl ether is not particularly limited, and examples thereof include polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, and polyoxyethylene polyoxypropylene lauryl ether; and polyoxypropylene alkyl ethers such as polyoxypropylene cetyl ether, polyoxypropylene isocetyl ether, polyoxypropylene stearyl ether, and polyoxypropylene oleyl ether.

[0051] The fatty acid alkanolamide is not particularly limited, and examples thereof include coconut fatty acid alkanolamides such as lauric acid diethanolamide, coconut fatty acid dimethanolamide, coconut fatty acid diethanolamide, and coconut fatty acid dipropanolamide.

[0052] The nonionic surfactant preferably contains a fatty acid ester, an aliphatic alcohol, or an aliphatic compound having a polyoxyalkylene structure in the molecule, as this improves the water-resistant viral infection prevention effect of the antiviral resin composition.

[0053] In this specification, "fatty acid esters having a polyoxyalkylene structure" are treated as fatty acid esters. "Aliphatic alcohols having a polyoxyalkylene structure" are treated as aliphatic alcohols. Therefore, "aliphatic compounds having a polyoxyalkylene structure in the molecule" do not have an ester structure, an alcoholic hydroxyl group, or a phenolic hydroxyl group in the molecule.

[0054] "Aliphatic compound" refers to a compound other than a compound having an aromatic ring structure. An aromatic ring structure means a structure in which carbon atoms are bonded in a ring and have aromaticity. In other words, an aromatic ring structure means a ring structure that follows the Huckel rule and has (4n+2) (n is a natural number) π electrons. Examples of aromatic ring structures include a benzene ring structure and a naphthalene ring structure.

[0055] The content of the fatty acid ester in the nonionic surfactant is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, and more preferably 95% by mass or more.

[0056] The content of the aliphatic alcohol in the nonionic surfactant is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, and more preferably 95% by mass or more.

[0057] In the nonionic surfactant, the content of the aliphatic compound having a polyoxyalkylene structure in the molecule is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, and more preferably 95% by mass or more.

[0058] The polyoxyalkylene structure means a repeating unit represented by the following general formula: -(R 2 -O)p- (wherein, R 2 represents an alkylene group having 1 to 14 carbon atoms, and p is the number of repeating units and is a natural number of 2 or more.

[0059] In the present invention, an alkylene group refers to a divalent atomic group resulting from the removal of two hydrogen atoms bonded to two different carbon atoms in an aliphatic saturated hydrocarbon, and includes both linear and branched atomic groups. Note that the branched group includes a group having one carbon atom (methyl group) bonded as a side chain.

[0060] Examples of the alkylene group include a methylene group [-CH-], an ethylene group [-CH-CH-], a propylene group [-CH(CH)-CH-], a trimethylene group [-CH-CH-CH-], a butylene group, an amylene group [-(CH)-], and a hexylene group, with an ethylene group and a propylene group being preferred, and an ethylene group being more preferred.

[0061] The fatty acid ester and / or the fatty alcohol preferably contains a polyoxyalkylene structure in the molecule, which allows the polyoxyalkylene structure to more effectively control moisture adsorption and release, thereby enhancing the water-resistant viral infection prevention effect of magnesium oxide.

[0062] Furthermore, aliphatic nonionic surfactants having a polyoxyalkylene structure in the molecule are more likely to segregate (bleed out) on the surface of the synthetic resin. Therefore, even if the antiviral resin composition present on the surface of a synthetic resin molded article is removed by cleaning such as wiping with water or by contact with human hands, it can be more effectively segregated (bleed out) on the surface of the synthetic resin molded article, and the excellent water-resistant viral infection prevention effect can be more stably imparted to the synthetic resin molded article.

[0063] The HLB value of the nonionic surfactant is preferably 15 or more, more preferably 16 or more, more preferably 17 or more, and even more preferably 18 or more. When the HLB value of the dispersant is 15 or more, the interaction between magnesium oxide and viruses can be improved, and the water-resistant virus infection prevention effect of the antiviral resin composition can be improved. In addition, the antiviral resin composition can be more effectively bled out onto the surface of the synthetic resin molded article, and the excellent water-resistant virus infection prevention effect can be more stably imparted to the synthetic resin molded article. The HLB value of the nonionic surfactant is a value calculated based on the following formula using the Griffin method: HLB value = 20 x sum of formula weights of hydrophilic moieties / molecular weight

[0064] The melting point of the auxiliary is preferably 30°C or higher, more preferably 35°C or higher, and more preferably 40°C or higher. The melting point of the auxiliary is preferably 80°C or lower, more preferably 75°C or lower, and still more preferably 70°C or lower. When the melting point of the auxiliary is 30°C or higher, the antiviral resin composition has good shape retention at room temperature, which is preferable. When the melting point of the auxiliary is 80°C or lower, the compounds constituting the antiviral resin composition are uniformly mixed by melting during processing of the antiviral resin composition, which is preferable. The melting point of the auxiliary refers to a value measured by differential scanning calorimetry in accordance with JIS K7121-1987.

[0065] The molecular weight of the auxiliary is preferably 200 or more, more preferably 250 or more. The molecular weight of the auxiliary is preferably 50,000 or less, more preferably 45,000 or less, more preferably 40,000 or less, more preferably 35,000 or less, more preferably 30,000 or less, and more preferably 25,000 or less. When the molecular weight of the auxiliary is within the above range, the water-resistant viral infection inhibitory effect of the viral infection inhibitor is improved. Note that when the auxiliary is an oligomer or polymer, the molecular weight of the auxiliary means the weight-average molecular weight.

[0066] In the present invention, the weight average molecular weight of the oligomer and polymer is a value measured by GPC (gel permeation chromatography) and converted into polystyrene.

[0067] For example, the measurement can be performed using the following measuring device and conditions: Gel permeation chromatograph: Waters Corporation, trade name "2690 Separations Model" Column: Showa Denko K.K., trade name "GPCKF-806L" Detector: differential refractometer Sample flow rate: 1 mL / min Column temperature: 40° C. Eluent: THF

[0068] The content of the auxiliary agent in the antiviral resin composition is preferably 0.1 parts by mass or more, more preferably 0.2 parts by mass or more, more preferably 0.3 parts by mass or more, more preferably 0.4 parts by mass or more, more preferably 0.5 parts by mass or more, more preferably 0.6 parts by mass or more, and more preferably 0.7 parts by mass or more, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, and the synthetic resin described below. The content of the auxiliary agent in the antiviral resin composition is preferably 1.8 parts by mass or less, more preferably 1.7 parts by mass or less, more preferably 1.6 parts by mass or less, more preferably 1.5 parts by mass or less, and more preferably 1.4 parts by mass or less, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, and the synthetic resin described below. When the content of the auxiliary agent is 0.1 parts by mass or more, the water-resistant viral infection prevention effect of the antiviral resin composition is improved. When the content of the auxiliary agent is 1.8 parts by mass or less, the strength of the antiviral resin composition is more easily maintained.

[0069] The mass ratio of the auxiliary agent content to the magnesium oxide content (auxiliary agent content / magnesium oxide content) is preferably 0.1 or more, more preferably 0.12 or more, more preferably 0.15 or more, more preferably 0.18 or more, and more preferably 0.19 or more. The mass ratio of the auxiliary agent content to the magnesium oxide content (auxiliary agent content / magnesium oxide content) is preferably 2.2 or less, more preferably 2.0 or less, more preferably 1.5 or less, more preferably 1.3 or less, more preferably 1.0 or less, more preferably 0.8 or less, more preferably 0.6 or less, and more preferably 0.4 or less. When the mass ratio of the auxiliary agent content to the magnesium oxide content (auxiliary agent content / magnesium oxide content) is 0.1 or more, it is possible to reduce deactivation of magnesium oxide due to moisture and reduce outflow of the antiviral resin composition due to water, and it is also possible to improve virus deactivation by magnesium oxide. When the mass ratio of the auxiliary agent content to the magnesium oxide content (auxiliary agent content / magnesium oxide content) is 2.2 or less, the water-resistant viral infection-preventing effect of the antiviral resin composition can be improved.

[0070] [Synthetic Resin] The antiviral resin composition contains a synthetic resin. The synthetic resin is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyethersulfone, polyarylate, polyetheretherketone, thermoplastic polyimide, polyamideimide, etc.), and thermosetting resins (e.g., phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, silicone resin, polyurethane, thermosetting polyimide, etc.). The synthetic resins may be used alone or in combination of two or more.

[0071] The content of the synthetic resin in the antiviral resin composition is preferably 88.2 parts by mass or more, more preferably 89.7 parts by mass or more, and still more preferably 90.4 parts by mass or more, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, and synthetic resin. The content of the synthetic resin in the antiviral resin composition is preferably 98.9 parts by mass or less, more preferably 97.8 parts by mass or less, and still more preferably 96.7 parts by mass or less, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, and synthetic resin.

[0072] [Antioxidant] The antiviral resin composition preferably contains an antioxidant. When the antiviral resin composition contains an antioxidant, the antiviral resin composition can maintain its excellent viral infection-inhibiting effect even after being exposed to irradiated light such as sunlight or light emitted from lighting (hereinafter, sometimes simply referred to as "irradiated light").

[0073] The mechanism by which an antiviral resin composition containing an antioxidant can maintain its excellent viral infection-inhibiting effect even after exposure to light has not been elucidated, but is presumed to be due to the following mechanism.

[0074] The antiviral resin composition is heated during a molding process in which the antiviral resin composition is molded to produce a virus infection-blocking molded article. This heating oxidizes the synthetic resin of the antiviral resin composition, generating carboxy groups in the molecular chains of the synthetic resin. The molecular chains with generated carboxy groups are more susceptible to cleavage by irradiated light at the portions where the carboxy groups are generated.

[0075] Furthermore, when the antiviral resin composition is used, the antiviral resin composition is usually exposed to light, and this light also causes the molecular chains of the synthetic resin to be cut over time.

[0076] It is presumed that when the molecular chains of the synthetic resin are cut and the chain length of the synthetic resin is shortened, the magnesium oxide in the antiviral resin composition becomes more likely to be covered by the synthetic resin with a short chain length, thereby reducing the viral infection-preventing effect of the antiviral resin composition.

[0077] Furthermore, the carboxyl groups formed in the molecular chains of the synthetic resin may inhibit the viral infection prevention effect of magnesium oxide.

[0078] Therefore, by adding an antioxidant to the antiviral resin composition, it is possible to reduce the generation of carboxy groups due to thermal degradation of the synthetic resin when the antiviral resin composition is heated, such as in a molding process, and to reduce the inhibition of the viral infection-preventing effect of magnesium oxide by the carboxy groups.

[0079] Furthermore, scission of molecular chains of the synthetic resin due to irradiated light can be reduced. Therefore, by including an antioxidant in the antiviral resin composition, it is possible to reduce the amount of magnesium oxide that is covered by the synthetic resin, and the antiviral resin composition can maintain its excellent viral infection-preventing effect even after being exposed to irradiated light.

[0080] The antioxidant is not particularly limited and may be a primary antioxidant or a secondary antioxidant, but a secondary antioxidant is preferred. The antioxidants may be used alone or in combination of two or more kinds.

[0081] The content of the primary antioxidant in the antioxidant is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0082] The content of the secondary antioxidant in the antioxidant is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0083] The primary antioxidant is a stabilizer that captures radicals generated by heat or light to stop radical reactions. The primary antioxidant is not particularly limited, and examples thereof include phenolic antioxidants.

[0084] Examples of phenolic antioxidants include 2,6-di-t-butyl-4-methylphenol, n-octadecyl-3-(3',5'-di-t-butyl-4'-hydroxyphenyl)propionate, tetrakis[3-(3,5-di-t-butyl-4-hydroxyphenyl)propionyloxymethyl]methane, tris[N-(3,5-di-t-butyl-4-hydroxybenzyl)]isocyanurate, butylidene-1,1-bis(2-methylpropanol), triethylene glycol bis[3-(3-t-butyl-4-hydroxy-5-methylphenyl)propionate], 3,9-bis{2-[3(3-t-butyl-4-hydroxy-5-methylphenyl)propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5]undecane, and the like, and these may be used alone or in combination of two or more.

[0085] The secondary antioxidant prevents autoxidation by ionizing hydroperoxide (ROOH), which is an intermediate in the autoxidation degradation of polyolefin resins caused by heat or light. The secondary antioxidant is not particularly limited, and examples thereof include phosphorus-based antioxidants and sulfur-based antioxidants, with phosphorus-based antioxidants being preferred.

[0086] Examples of phosphorus-based antioxidants include tridecyl phosphite, tris(tridecyl)phosphite, tristearyl phosphite, triphenyl phosphite, trinonylphenyl phosphite, bis(tridecyl)pentaerythritol diphosphite, distearyl pentaerythritol diphosphite, bis(decyl)pentaerythritol diphosphite, tris(2,4-di-t-butylphenyl)phosphite, 3,9-bis(octadecyloxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, bis(2,4-di-t-butyl-6-methyl) diethyl(3,5-di-t-butyl-4-hydroxybenzyl)phosphonate, stearyl acid phosphate zinc salt, and the like. Of these, tris(2,4-di-t-butylphenyl)phosphite and 3,9-bis(octadecyloxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane are preferred.

[0087] Examples of sulfur-based antioxidants include dilauryl-3,3'-thio-dipropionate, dimyristyl-3,3'-thio-dipropionate, distearyl-3,3'-thio-dipropionate, and pentaerythritol tetrakis(3-laurylthio-propionate).

[0088] The content of the antioxidant in the antiviral resin composition is preferably 0.01 parts by mass or more, more preferably 0.04 parts by mass or more, and more preferably 0.05 parts by mass or more, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, synthetic resin, and antioxidant. The content of the antioxidant in the antiviral resin composition is preferably 5 parts by mass or less, more preferably 1 part by mass or less, and more preferably 0.5 parts by mass or less, per 100 parts by mass of the total of the magnesium oxide, auxiliary agent, synthetic resin, and antioxidant. When the content of the antioxidant is 0.01 parts by mass or more, the antiviral resin composition can maintain an excellent viral infection-inhibiting effect even after exposure to light. When the content of the antioxidant is 5 parts by mass or less, the physical properties of the antiviral resin composition are less likely to be impaired, which is preferable.

[0089] In the antiviral resin composition, the total content of magnesium oxide, the auxiliary agent, the synthetic resin, and the antioxidant is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0090] The antiviral resin composition may contain additives such as plasticizers, curing agents, extenders, fillers, reinforcing agents, colorants, flame retardants, flame retardant aids, fluorescent brighteners, impact resistance modifiers, antifogging agents, flow improvers, plasticizers, and light stabilizers, within amounts that do not impair the antiviral resin composition's physical properties.

[0091] [Antiviral Resin Composition] The antiviral resin composition contains magnesium oxide, an auxiliary agent, and a synthetic resin. The method for producing the antiviral resin composition is not particularly limited, and the antiviral resin composition can be produced by mixing magnesium oxide, the auxiliary agent, and the synthetic resin with compounds such as an antioxidant that are added as needed in a general manner using an extruder or the like.

[0092] The term "viral infection inhibitory effect" refers to the effect of eliminating or reducing the infectivity of viruses to cells, or preventing them from replicating in cells even if they infect. Examples of methods for confirming the presence or absence of such viral infectivity include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for plastics and non-porous surface products other than textile products. The Society of International Antimicrobial Association (SIAA) certifies the antiviral finish mark to products that meet the standards for the safety and antiviral effect of antiviral processing agents. The standard for antiviral effect is a difference (antiviral activity value) of 2.0 or more between the common logarithm of the viral infectivity of a blank product (product without antiviral processing agent) and the common logarithm of the viral infectivity of a processed product (product with antiviral processing agent added) in the evaluation according to ISO 21702. It is sufficient for an antiviral resin composition to have an antiviral activity value of 2.0 or more for any virus.

[0093] Other examples include the plaque method and hemagglutination unit (HAU) assay described in "Medical and Pharmaceutical Virology" (first published in April 1990).

[0094] The viral infection-preventing effect of an antiviral resin composition can be measured, for example, as follows: The antiviral resin composition is press-molded to produce a sheet-like synthetic resin molded article with an average thickness of 1 mm. The surface of the obtained synthetic resin molded article is wiped with a flat square nonwoven fabric with sides of 10 cm by moving the nonwoven fabric back and forth 10 times, and this synthetic resin molded article is used as a test specimen.

[0095] The obtained test specimen is subjected to an antiviral test (test time: 24 hours) in accordance with ISO 21702. The virus suspension is subjected to the plaque method for 10 minutes after the reaction (start of the test) to measure the virus infectivity (common logarithm) (PFU / cm 2 ) is calculated.

[0096] A blank reference body was prepared in the same manner as above, except that a synthetic resin molded body was prepared by press molding using only synthetic resin. Based on this blank reference body, the virus infectivity (common logarithm) (PFU / cm) was calculated in the same manner as above. 2 ) is calculated.

[0097] The antiviral activity value is calculated by subtracting the viral infectivity of the test sample from the viral infectivity of the blank reference sample.

[0098] The antiviral resin composition has a viral infection-preventing effect against various viruses, and exhibits excellent viral infection-preventing effect against both enveloped and non-enveloped viruses.

[0099] Examples of enveloped viruses include influenza viruses (e.g., types A and B), rubella viruses, Ebola viruses, coronaviruses (e.g., SARS virus, novel coronavirus (SARS-CoV-2)), measles viruses, varicella-zoster viruses, herpes simplex viruses, mumps viruses, arboviruses, respiratory syncytial viruses, hepatitis viruses (e.g., hepatitis B virus, hepatitis C virus), yellow fever viruses, AIDS viruses, rabies viruses, hantaviruses, dengue viruses, Nipah viruses, and lyssaviruses.

[0100] Examples of non-enveloped viruses include adenovirus, norovirus, rotavirus, human papillomavirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, poliovirus, and rhinovirus.

[0101] The antiviral resin composition can be molded into a desired shape by a general-purpose synthetic resin molding method, such as extrusion molding, injection molding, or blow molding, to obtain a virus infection-preventing molded article having a virus infection-preventing effect.

[0102] The shape of the virus infection-blocking molded article is not particularly limited and can be appropriately selected depending on the application and purpose of the virus infection-blocking molded article. Examples of the shape of the virus infection-blocking molded article include plate-like, plate-like, rod-like, sheet-like, film-like, cylindrical, ring-like, circular, elliptical, polygonal, irregularly shaped, hollow, frame-like, box-like, panel-like, and other shapes suited to various applications.

[0103] Examples of uses for the virus infection-preventing molded article include structural component parts, portable electronic device components, vehicle components, medical device components, housings for electronic components, and food and pharmaceutical containers.

[0104] The resulting virus infection-blocking molded article has an excellent virus infection-blocking effect due to the antiviral resin composition. The antiviral resin composition contained in the virus infection-blocking molded article exhibits an excellent water-resistant virus infection-blocking effect, and can maintain its excellent virus infection-blocking effect despite moisture from cleaning operations such as wiping with water, contact with human hands, food and beverages, etc.

[0105] The antiviral resin composition may be used as a synthetic resin molding masterbatch, and the synthetic resin molding masterbatch may be mixed with a synthetic resin raw material to produce a virus infection-blocking molded article using a general-purpose synthetic resin molding method. The synthetic resin used in the synthetic resin molding masterbatch may be any of the synthetic resins exemplified above. Only one type of synthetic resin may be used, or two or more types may be used in combination.

[0106] The synthetic resin molding masterbatch is preferably in the form of resin pellets, as these have excellent moldability. By melting and molding the resin pellets, a virus infection-preventing molded article having excellent virus infection-preventing effects can be obtained.

[0107] The shape of the resin pellets is not particularly limited, and examples thereof include spherical, cylindrical, and prismatic shapes. From the viewpoint of pellet shape stability, a cylindrical shape is preferred. The maximum length dimension of the resin pellets is preferably 1 mm or more, more preferably 3 mm or more. The maximum length dimension of the resin pellets is preferably 10 mm or less, more preferably 7 mm or less.

[0108] The synthetic resin molding masterbatch can be used by mixing with other resin materials. The other resin materials may be resin pellets. The synthetic resin molding masterbatch and the other resin materials are mixed to obtain a mixed resin material, and then the mixed resin material is molded to obtain a virus infection-preventing molded article having excellent virus infection-preventing effect.

[0109] The content of the antiviral resin composition in 100% by mass of the masterbatch for synthetic resin molding is preferably 10% by mass or more, more preferably 15% by mass or more, and still more preferably 20% by mass or more. The content of the antiviral resin composition in the masterbatch for synthetic resin molding is preferably 80% by mass or less, more preferably 70% by mass or less, and still more preferably 60% by mass or less.

[0110] The content of magnesium oxide constituting the antiviral resin composition in 100% by mass of the masterbatch for synthetic resin molding is preferably 20% by mass or more, more preferably 30% by mass or more, and still more preferably 50% by mass or more. The content of magnesium oxide constituting the antiviral resin composition in 100% by mass of the masterbatch for synthetic resin molding is preferably 80% by mass or less, more preferably 70% by mass or less, and still more preferably 60% by mass or less.

[0111] The content of the auxiliary constituting the antiviral resin composition in 100% by mass of the masterbatch for synthetic resin molding is preferably 4% by mass or more, more preferably 6% by mass or more, and still more preferably 10% by mass or more. The content of the magnesium oxide constituting the antiviral resin composition in 100% by mass of the masterbatch for synthetic resin molding is preferably 16% by mass or less, more preferably 14% by mass or less, and still more preferably 12% by mass or less.

[0112] The present invention will be described in more detail below using examples, but the present invention is not limited thereto. Specific numerical values ​​of the blending ratios (content ratios), physical property values, parameters, etc. used in the following description can be replaced with the upper limit values ​​(numeric values ​​defined as "equal to or less than") or lower limit values ​​(numeric values ​​defined as "equal to or more than" or "exceeding") of the corresponding blending ratios (content ratios), physical property values, parameters, etc. described in the "Description of Embodiments."

[0113] The compounds used in the production of the antiviral resin compositions of the Examples and Comparative Examples are shown below. [Magnesium oxide] Light-burned magnesium oxide 1 (manufactured by Kyowa Chemical Industry Co., Ltd., trade name "Kyowamag 30", MgO: 98 mass%, CaO: 0.63 mass%, and Fe2O3: 0.018 mass%) Light-burned magnesium oxide 2 (manufactured by Kyowa Chemical Industry Co., Ltd., trade name "Kyowamag MF30", MgO: 99.7 mass%, CaO: 0.06 mass%, and Fe2O3: 0.0012 mass%) Light-burned magnesium oxide 3 (manufactured by Kyowa Chemical Industry Co., Ltd., trade name "Kyowamag 150", MgO: 98 mass%, CaO: 0.78 mass%, and Fe2O3: 0.018 mass%) Light-burned magnesium oxide 4 (manufactured by Kyowa Chemical Industry Co., Ltd., trade name "Kyowamag 50", MgO: 98 mass%, CaO: 0.78 mass%, and Fe2O3: 0.018 mass%) Light-burned magnesium oxide 5 (manufactured by Tateho Chemical Co., Ltd., trade name "TATEHOMAG 700", MgO: 99.2 mass%, CaO: 0.42 mass%, SiO: 0.16 mass%, FeO: 0.03 mass%). Light-burned magnesium oxide 6 (manufactured by Tateho Chemical Co., Ltd., trade name "TATEHOMAG 500", MgO: 99 mass%, CaO: 0.42 mass%, SiO: 0.11 mass%, FeO: 0.04 mass%). Light-burned magnesium oxide 7 (manufactured by Tateho Chemical Co., Ltd., trade name "TATEHOMAG H-10", MgO: 98.9 mass%, CaO: 0.4 mass%, SiO: 0.1 mass%, FeO: 0.04 mass%); Light-burned magnesium oxide 8 (manufactured by Ube Material Industries, Ltd., product name "UC-95HT"), MgO: 97.9 mass%, CaO: 0.54 mass%, SiO: 0.06 mass%, FeO: 0.03 mass%)

[0114] [Auxiliaries] Sorbitan monostearate (manufactured by Kao Corporation, trade name "Rheodol SP-S10V") Saturated fatty acid monoglyceride 1 (manufactured by Kao Corporation, trade name "Excel VS-95", palmitic acid monoglyceride: 35 to 45% by mass, stearic acid monoglyceride: 50 to 60% by mass) Saturated fatty acid monoglyceride 2 (manufactured by Kao Corporation, trade name "Excel P-40S", palmitic acid monoglyceride: 30 to 40% by mass, stearic acid monoglyceride: 50 to 60% by mass) Polyethylene glycol distearate (manufactured by Kao Corporation, trade name "Emanon 3299VB") Propylene glycol monostearate (manufactured by Riken Vitamin Co., Ltd., trade name "Rikemal PS-100") Cetostearyl alcohol (manufactured by Kao Corporation, trade name "Kalcol 6850") Polyethylene glycol 1 (manufactured by NOF Corporation) Polyethylene glycol 2 (manufactured by NOF Corporation, trade name "PEG #6000") Polyethylene glycol 3 (manufactured by NOF Corporation, trade name "PEG #11000") Polyethylene glycol 4 (manufactured by NOF Corporation, trade name "PEG #20000")

[0115] [Synthetic resin] Polypropylene (PP)

[0116] [Antioxidants] Antioxidant 1 [tris(2,4-di-t-butylphenyl)phosphite, manufactured by BASF Japan Ltd., trade name "Irgafos 168"] Antioxidant 2 [3,9-bis(octadecyloxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, manufactured by ADEKA Corporation, trade name "ADEKA STAB PEP-8"]

[0117] The specific surface area and D50 particle size of the magnesium oxide were measured as described above, and the results are shown in Table 1. The HLB value, molecular weight, and melting point of the auxiliary were measured as described above, and the results are shown in Table 1.

[0118] (Examples 1 to 17 and Comparative Examples 1 to 8) Antiviral resin compositions were prepared by heating to 220°C and uniformly mixing the types and amounts of magnesium oxide, auxiliary agent, and synthetic resin shown in Table 1. In the antiviral resin compositions, the contents of magnesium oxide, auxiliary agent, and synthetic resin are shown in the "Content (parts by mass)" column as "magnesium oxide content / auxiliary agent content / synthetic resin content."

[0119] (Examples 18 and 19) Antiviral resin compositions were prepared by heating to 220°C and uniformly mixing the types and predetermined amounts of magnesium oxide, auxiliary agent, synthetic resin, and antioxidant shown in Table 3. In the antiviral resin composition, the contents of magnesium oxide, auxiliary agent, synthetic resin, and antioxidant were shown in the "Contents (parts by mass)" column in the following format: "magnesium oxide content / auxiliary agent content / synthetic resin content / antioxidant content."

[0120] For the antiviral resin compositions obtained in the examples and comparative examples, the antiviral activity values ​​initially and after the water resistance test were measured in the manner described below, and the results are shown in the "Initial" and "After the water resistance test" columns of "Antiviral activity value" in Tables 2 and 4, respectively.

[0121] For the antiviral resin compositions obtained in Examples 7, 18, and 19, the antiviral activity values ​​after the light resistance test were measured in the following manner, and the results are shown in the column of "After light resistance test" under "Antiviral activity value" in Table 4.

[0122] (Initial antiviral activity value) The antiviral resin composition was press-molded to prepare a sheet-like synthetic resin molded product having an average thickness of 1 mm. The surface of the obtained synthetic resin molded product was wiped with a flat square nonwoven fabric having sides of 10 cm by moving the nonwoven fabric back and forth 10 times, and this synthetic resin molded product was used as a test specimen.

[0123] The obtained test specimens were subjected to an antiviral test against feline calicivirus (test time: 24 hours) in accordance with ISO 21702. The virus suspension was subjected to the plaque method for 10 minutes after the reaction (start of the test) to measure the virus infectivity (common logarithm) (PFU / cm 2 ) was calculated.

[0124] A blank reference body was prepared in the same manner as above, except that a synthetic resin molded body was prepared by press molding using only synthetic resin. Based on this blank reference body, the virus infectivity (common logarithm) (PFU / cm) was calculated in the same manner as above. 2 ) was calculated.

[0125] The initial antiviral activity value was calculated by subtracting the viral infectivity of the test sample from the viral infectivity of the blank reference sample.

[0126] (Antiviral activity value after water resistance test) The antiviral resin composition was press-molded to produce a sheet-like synthetic resin molded product having an average thickness of 1 mm. The surface of the obtained synthetic resin molded product was wiped with a flat square nonwoven fabric having a side length of 10 cm by moving the nonwoven fabric back and forth 10 times.

[0127] A water resistance test was conducted on the synthetic resin molded article in accordance with the water resistance test for water resistance category 1 specified by SIAA. The antiviral test was conducted in the same manner as for the initial antiviral activity value, except that a test specimen was prepared by removing water adhering to the surface of the synthetic resin molded article after the water resistance test with a cloth, and the antiviral activity value after the water resistance test was calculated.

[0128] (Antiviral activity value after light resistance test) The antiviral resin composition was press-molded to produce a sheet-like synthetic resin molded product having an average thickness of 1 mm. The surface of the obtained synthetic resin molded product was wiped with a flat square nonwoven fabric having a side length of 10 cm by moving the nonwoven fabric back and forth 10 times.

[0129] The synthetic resin molded body was irradiated with a xenon lamp at a wavelength of 365 nm with an irradiation intensity of 60 W / m 2 The antiviral test was performed in the same manner as for the initial antiviral activity value, except that the test specimen was prepared by irradiating for 10 hours so that the antiviral activity value after the light resistance test was calculated.

[0130]

[0131]

[0132]

[0133]

[0134] The antiviral resin composition of the present invention has excellent water resistance and can be used to produce a virus infection-blocking molded article that maintains its excellent virus infection-blocking effect even after contact with water (hereinafter referred to as "water-resistant virus infection-blocking effect").

[0135] (Cross-reference to related applications) This application claims priority to Japanese Patent Application No. 2024-092634, filed on June 6, 2024, the disclosure of which is incorporated herein by reference in its entirety.

Claims

1. An antiviral resin composition comprising magnesium oxide, an auxiliary agent, and a synthetic resin, wherein the auxiliary agent comprises a nonionic surfactant or a polyoxyalkylene glycol.

2. The antiviral resin composition according to claim 1, wherein the HLB value of the auxiliary agent is 15 or more.

3. The antiviral resin composition according to claim 1 or 2, characterized in that the nonionic surfactant contains a fatty acid ester, an aliphatic alcohol, or an aliphatic compound having a polyoxyalkylene structure in the molecule.

4. The specific surface area of ​​the magnesium oxide is 20 to 100 m 2 The antiviral resin composition according to claim 1 or 2, characterized in that:

5. The antiviral resin composition according to claim 1 or 2, characterized in that the magnesium oxide has a D50 particle size of 10 μm or less.

6. The antiviral resin composition according to claim 1 or 2, characterized in that the mass ratio of the content of the auxiliary agent to the content of the magnesium oxide (content of the auxiliary agent / content of the magnesium oxide) is 0.1 to 2.

2.

7. The antiviral resin composition according to claim 1 or 2, further comprising an antioxidant.

8. A masterbatch for synthetic resin molding, comprising the antiviral resin composition according to claim 1 or 2.

9. A molded article that prevents viral infection, characterized by containing the antiviral resin composition according to claim 1 or 2.

Images